Cipla Limited has entered into an exclusive supply and marketing agreement with Pfizer for select brands in India. This agreement, effective December 19, 2025, grants Cipla exclusive rights to market and distribute brands such as Corex, Dolonex, Neksium, and Dalacin C. Pfizer will continue to manufacture and supply these medicines. The partnership aims to enhance the availability of these key brands across the country for a period of 5 years.
Partnership Overview
Cipla has announced a strategic partnership with Pfizer, effective as of December 19, 2025. This agreement focuses on exclusive supply and marketing rights for a range of Pfizer’s established pharmaceutical brands within the Indian market. The collaboration aims to leverage Cipla’s extensive distribution network and market reach to improve the accessibility of these medications.
Key Brands Included
Under the agreement, Cipla gains exclusive rights to market and distribute the following Pfizer brands for a period of 5 years:
- Corex
- Dolonex
- Neksium
- Dalacin C
Cipla’s Role
Cipla will now be responsible for marketing, distributing, and selling these brands within India. This arrangement is expected to strengthen Cipla’s portfolio and expand its presence in key therapeutic areas. The company anticipates that this agreement will ensure wider reach and depth across India for the mentioned medicines.
Pfizer’s Continued Support
While Cipla takes on the marketing and distribution responsibilities, Pfizer will continue to manufacture and source the medicines, ensuring a consistent supply to meet market demand. This collaboration leverages the strengths of both companies to optimize the availability of these established pharmaceutical products.
Source: BSE
